IMC-003

Biologic (subtype unspecified)

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Featured evidence outside this drug's tracked markets:NCT07593027 · Pulmonary Arterial Hypertension PAH · Phase 1/2 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Other / comorbidity
NCT07593027 · ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
2026-04-30 – 2027-11-30 · Pulmonary Arterial Hypertension PAH
What this study did
Phase 1 (1)
Other / comorbidity

Competitive landscape

Other Activin receptor type IIA (ActRIIA) drugs

Sotatercept, LAE102, HS235. Compare all 4 Activin receptor type IIA (ActRIIA) drugs

3 other tracked programmes target this mechanism, 2 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
IMC-003: this drugPhase 1/2Biologic (subtype unspecified)Activin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary
Sotatercept (Winrevair)
Approved(overall)
Protein / enzyme therapeuticActivin receptor type IIA (ActRIIA)Reliable signal
NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5)
NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025).
LAE102
Phase 2(overall)
Monoclonal antibodyActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary
HS235
Phase 1/2(overall)
PeptideActivin receptor type IIA (ActRIIA)Weak signalNo reviewed efficacy summary

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow IMC-003 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
May 2027 (1)
Phase 1Healthy Postmenopausal WomenRecruiting
Est. primary completion 2027-05-20 · NCT07118085 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Pulmonary Arterial Hypertension PAHRecruiting
Est. primary completion 2027-10-31 · NCT07593027 · CT.gov ↗
What to watch

See the full readout calendar ↗